An 86-year-old female patient with Parkinson's disease was admitted to a cardiology outpatient clinic for routine check-up. She had coronary artery bypass grafting 12 years ago. The patient was taking dabigatran 110 mg twice a day due to atrial fibrillation, metoprolol succinate 100 mg, perindopril 10 mg, atorvastatin 20 mg, and trimetazidine 35 mg twice a day. She was prescribed trimetazidine on account of chest pain unrelated to exertion 9 months ago. Electrocardiography revealed atrial fibrillation, with a heart rate of 74 per minute. Ejection fraction of 42% and moderate mitral regurgitation were detected on the echocardiography. Her effort capacity was too limited owing to Parkinsonism. Therefore, it could not be assessed whether exertional angina or dyspnea was present. A neurology consultation was recommended due to severe bradykinesia and postural instability during walking. However, it was ascertained that she had been on close follow-up by the neurology department for 7 months, and no significant clinical improvement was provided, even with dose increments of levodopa and, thereafter, addition of carbidopa and benserazide, respectively.
The patient's physical performance deteriorated in the last 7 months by virtue of accelerated progression of Parkinsonism. There was something bizarre in the patient's clinical status. She was doing well with only a moderate dose of levodopa, and it is questionable what happened and why she got worse rapidly. The physician was remembering an adverse effect of trimetazidine, which leads to extrapyramidal side effects. However, he was not quite sure whether trimetazidine could possibly cause it. After searching PubMed for adverse drug reactions of trimetazidine, case reports with Parkinsonism after trimetazidine use were detected. Trimetazidine was discontinued. After 3 months, the patient was taking only levodopa again, and the outcome was quite favorable after discontinuation of trimetazidine, with an almost full recovery to her past physical performance.
Trimetazidine is quite frequently used in cardiology practice as an anti-ischemic agent, albeit it might cause heartburn, nausea, and vomiting, as well as extrapyramidal side effects. The 2013 ESC guidelines on the management of stable coronary artery disease revealed a contraindication of trimetazidine in patients with Parkinson's disease.
As a cardiologist, we should learn all adverse effects of drugs that we are using in our daily cardiology practice, as well as pharmaceutical effects we already know well. This case teaches cardiologists to prescribe trimetazidine exactly when it is needed, and it may lead to Parkinson-like side effects, even in patients without Parkinson's disease. There is a main principal precept of bioethics that all medical students are taught in school: primum non nocere.